US FDA’s Patient-Focused Drug Development Program Meetings Evolve With Technology Focus

 
• By Derrick Gingery

A recent externally-led PFDD meeting on kidney xenotransplantation, rather than a specific disease, allowed for more tailored patient comments on the procedure, which could impact development plans going forward.

evolution
The FDA's PFDD program is evolving to tackle new areas for patient input. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards